AQB 565

Drug Profile

AQB 565

Alternative Names: AQB 565

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aequus BioPharma
  • Class Antigouts; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Corticotropin receptor agonists; Melanin stimulants; Melanocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gout

Most Recent Events

  • 11 Nov 2016 Preclinical trials in Gout in USA (unspecified route)
  • 11 Nov 2016 Preclinical results presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016) .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top